Literature DB >> 31553058

Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression.

Samia Hannaoui1, Maria Immaculata Arifin1, Sheng Chun Chang1, Jie Yu1, Preetha Gopalakrishnan1, Katsumi Doh-Ura2, Hermann M Schatzl1, Sabine Gilch1.   

Abstract

Chronic wasting disease (CWD) is a prion disease of free-ranging and farmed cervids that is highly contagious because of extensive prion shedding and prion persistence in the environment. Previously, cellulose ether compounds (CEs) have been shown to significantly extend the survival of mice inoculated with mouse-adapted prion strains. In this study, we used CEs, TC-5RW, and 60SH-50, in vitro and in vivo to assess their efficacy to interfere with CWD prion propagation. In vitro, CEs inhibited CWD prion amplification in a dose-dependent manner. Transgenic mice over-expressing elk PrPC (tgElk) were injected subcutaneously with a single dose of either of the CEs, followed by intracerebral inoculation with different CWD isolates from white tailed deer, mule deer, or elk. All treated groups showed a prolonged survival of up to more than 30 % when compared to the control group regardless of the CWD isolate used for infection. The extended survival in the treated groups correlated with reduced proteinase K resistance of prions. Remarkably, passage of brain homogenates from treated or untreated animals in tgElk mice resulted in a prolonged life span of mice inoculated with homogenates from CE-treated mice (of + 17%) even in the absence of further treatment. Besides the delayed disease onset upon passage in TgElk mice, the reduced proteinase K resistance was maintained but less pronounced. Therefore, these compounds can be very useful in limiting the spread of CWD in captive and wild-ranging cervids.
© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.

Entities:  

Keywords:  PrPSc conformation; cellulose ether; chronic wasting disease; prions; prophylactic; therapeutic

Year:  2019        PMID: 31553058     DOI: 10.1111/jnc.14877

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

Review 1.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

2.  Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice.

Authors:  Tahir Ali; Samia Hannaoui; Satish Nemani; Waqas Tahir; Irina Zemlyankina; Pearl Cherry; Su Yeon Shim; Valerie Sim; Hermann M Schaetzl; Sabine Gilch
Journal:  Acta Neuropathol Commun       Date:  2021-04-01       Impact factor: 7.801

3.  Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics.

Authors:  Mingxuan Ding; Kenta Teruya; Weiguanliu Zhang; Hae Weon Lee; Jue Yuan; Ayumi Oguma; Aaron Foutz; Manuel V Camacho; Marcus Mitchell; Justin J Greenlee; Qingzhong Kong; Katsumi Doh-Ura; Li Cui; Wen-Quan Zou
Journal:  Mol Neurobiol       Date:  2021-05-13       Impact factor: 5.590

Review 4.  Gene-Edited Cell Models to Study Chronic Wasting Disease.

Authors:  Simrika Thapa; Cristobal Marrero Winkens; Waqas Tahir; Maria I Arifin; Sabine Gilch; Hermann M Schatzl
Journal:  Viruses       Date:  2022-03-15       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.